[SCHEDULE 13G/A] Quantum Biopharma Ltd. Class B Subordinate Voting Shares SEC Filing

Rhea-AI Filing Summary

Malone Wealth Ventures LLC ("MWV") has filed Amendment No. 3 to Schedule 13G for Quantum Biopharma Ltd. (QNTM) dated 10 July 2025. The investment adviser, organized in the United States, now reports beneficial ownership of 735,148 common shares—approximately 19.4 % of Quantum Biopharma’s outstanding stock.

MWV discloses sole voting power over 103,601 shares and sole dispositive power over the full 735,148-share position; no shares are subject to shared voting or dispositive authority. The filing is made on Schedule 13G, signalling the position is considered passive under SEC rules. MWV affirms the holdings were acquired in the ordinary course of business and not for the purpose of influencing control, in line with Rule 13d-1(b)(1)(ii)(E) applicable to investment advisers.

Clients of MWV retain the economic rights to dividends or sale proceeds, but no single client holds more than 5 % of the class. The certification section confirms the accuracy and completeness of the disclosure, with the document signed by President and CEO Kevin M. Malone.

Insights

Securities Analyst

TL;DR – MWV’s passive stake rises to 19.4 %, signalling material but non-controlling ownership.

The near-20 % holding makes MWV the largest disclosed shareholder, potentially adding liquidity support and reflecting confidence in QNTM’s prospects. Because the filing is a 13G (not 13D), the firm represents it has no activist agenda, reducing the likelihood of near-term governance disruptions. Investors should nonetheless watch for future amendments that could push ownership beyond 20 % or convert to a 13D, which would indicate an intent to influence strategy.

Corporate Governance Expert

TL;DR – Large passive position eases control concerns but concentrates voting power.

A single investment adviser holding almost one-fifth of the float can sway routine matters even without an activist mandate. While MWV’s certification limits control ambitions, its dispositive authority over 735k shares means board proposals requiring simple majorities could hinge on its vote. The disclosure is therefore impactful for governance monitoring, though not immediately threatening.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Quantum Biopharma Ltd.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

74764Y205

(CUSIP Number)

07/10/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74764Y205

1

Names of Reporting Persons

Malone Wealth Ventures LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 109,765.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 689,421.00
8	Shared Dispositive Power

9

Aggregate Amount Beneficially Owned by Each Reporting Person

689,421.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

19.9 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: Les Gro

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Quantum Biopharma Ltd.
(b)	Address of issuer's principal executive offices: 55 UNIVERSITY AVENUE, SUITE 1003, 55 UNIVERSITY AVENUE, SUITE 1003, TORONTO, ONTARIO, CANADA, M5J 2H7.
Item 2.
(a)	Name of person filing: Malone Wealth Ventures LLC
(b)	Address or principal business office or, if none, residence: 9201 W State St. Ste 126 Boise, ID 83714
(c)	Citizenship: United States
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 74764Y205
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 735148
(b)	Percent of class: 19.4 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 103601
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 735148
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Clients of Malone Wealth Ventures LLC have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, the securities reported herein. No individual client is known to have such interest relating to more than five percent of the class.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Malone Wealth Ventures LLC

Signature:	Kevin M Malone
Name/Title:	President and CEO
Date:	07/10/2025